Studieoverzicht
Study name: ARTEMIDE-01
| Histology | NSCLC |
|---|---|
| Tumor stage | Stage IV |
| Host / recruiting sites | LUMC |
| Enrollment | Closed |
| Therapy line | First line (1L) , Later line (≥2L) |
| Design |
Open label, fase 1/ 2 dosis escalatie en expansie studie |
| Intervention | AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody (Rilvegostomig) |
| Key outcome parameters | Safety en tolerability, ORR, PFS |
| Key inclusion criteria | Stadium IV NSCLC, ECOG 0-1 Part C: CPI-naiëf stadium IV NSCLC met PDL1 ≥1% Part D: CPI-naiëf stadium IV NSCLC met PDL1 ≥50% |
| Key exclusion criteria | Driver mutatie Symptomatische CNS metastasen Steroiden (equivalent >10mg prednisone) |
| Contact information | Log in voor de contactinformatie |